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The development of Tyrosinase inhibitors (TYRIs) could represent an efﬁcacious strategy for pharma-
cological intervention on skin pathologies related to aberrant production of melanin. Based on in silico
studies we designed and tested a library of twenty-four compounds bearing the 4-(4-ﬂuorobenzyl)
piperazin-1-yl]-fragment. As result, we identiﬁed several compounds with excellent inhibit effects at low
micromolar concentration against TYR from Agaricus bisporus (TyM). Among them, compound 25
(IC50¼ 0.96 mM) proved to be ~20-fold more potent than the reference compound kojic acid
(IC50¼ 17.76 mM) having wide applications in the cosmetics and pharmaceutical industries. The mode of
interaction of active inhibitor 25 was deciphered by means of crystallography as well as molecular
docking and these results were consistent with kinetic experiments. Moreover, the identiﬁed compound
25 exhibited no considerable cytotoxicity and showed anti-melanogenic effects on B16F10 melanoma
cells. Therefore, a combination of computational and biochemical approaches could represent a rational
guidelines for further structural modiﬁcation of this class of compounds as future anti-melanogenic
agents.
© 2019 Elsevier Masson SAS. All rights reserved.1. Introduction
Tyrosinases (TYRs, EC 1.14.18.1) are largely distributed enzymes
in bacteria, fungi, insects, plants, and mammalians. TYR is the key
enzyme that catalyzes the conversion of the substrate tyrosine into
the intermediate product o-quinone (dopaquinone), which is
further oxidized into eumelanin and pheomelanin through other
interrelated enzymatic and non-enzymatic reactions [1].garicus bisporus; TYRIs, TYR
say interference compounds.
aceutical, and Environmental
e Palatucci 13, I-98168, Mes-
served.In humans, melanin is responsible for absorbing light in order to
protect skin cells from UVB-radiation damage. However, the aber-
rant production and accumulation of melanin in the face and neck
usually cause common pigmentary disorders, such as melasma and
post-inﬂammatory hyperpigmentation, and pose a serious
aesthetic problem [2].
TYR inhibition is one strategy aimed at controlling the produc-
tion of melanin; therefore, the development of TYR inhibitors
(TYRIs) has gained high interest in the therapies of skin pathologies
as well as in dermocosmetic treatments. Several well-known TYRIs
as hydroquinone, arbutin, kojic acid, ascorbic acid (see Chart 1) and
other molecules from natural sources are anti-melanin and whit-
ening agents, but they have been reported to be problematic due to
various adverse side effects, such as contact dermatitis, irritation,
leukoderma, hypochromia, and ochronosis [2e6].
Chart 1. Chemical structures of representative TYRIs (1e4) and binding mode of kojic acid (1) in complex with TYR from Bacillus megaterium (PDB: 5I38 [8]).
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loenzymes with a conserved catalytic domain, which comprises six
histidine residues and two copper ions (CuA and CuB) [7] as
demonstrated by X-ray structures from Bacillus megaterium (PDB:
5I38) [8] (see Chart 1), Streptomyces castaneoglobisporus (PDB:
5Z0D), Aspegilus oryzae (PDB: 3W6W), Agaricus bisporus (PDB:
2Y9X [9], and Juglans regia (PDB: 5CE9) [10].
Based on a combination of crystallographic and docking studies
on TYRs from Bacillus megaterium (TyBm) and TyM, we have pre-
viously designed a new class of TYRIs that proved to be more
effective than the well-known inhibitor kojic acid (1, KA) [11e13].
Among them, the 4-(4-ﬂuorobenzyl)piperazin-1-yl]phenyl-
methanone (5a) and 4-(4-ﬂuorobenzyl)piperazin-1-yl](2-
methylphenyl)methanone (5b) (see Chart 2) displayed inhibitory
effects at low micromolar concentrations toward TyM [13].
The ligand-enzyme binding proﬁle of the best active compound
5b (IC50 value of 5.25 mM) has been explored by means of theo-
retical and experimental studies [13]. In more detail, Fig. 1 (panel A)
shows the docking pose of compound 5b (magenta) [13] in the
active site of TyM (PDB: 2Y9X). Whereas, panel B describes the
binding mode of the same compound 5b (yellow) in complex with
TyBm as obtained from the crystal structure (PDB: 5OAE) [13].
These combined results highlighted the ability of inhibitor 5b to
occupy both active sites of TyM and TyBm. The 4-ﬂuorobenzyl
moiety is positioned towards the Cu ions and the oxygen of the
amide group is oriented towards Arg268 in TyM or Arg209 in TyBm.
Instead, the 2-methylphenyl moiety appears to be directed to the
top area of the catalytic cavity of the two studied TYRs.
As continuation of this study we chose to better understand the
molecular determinant controlling the interactions in the top re-
gion of the cavity for this series of 4-(4-ﬂuorobenzyl)piperazine-Chart 2. Chemical structures of previously identiﬁed TYRIs bearing 4-(4-ﬂuorobenzyl)
piperazine moiety.derivatives (e.g. 5a and 5b). To this end, we carried out a compu-
tational approach aimed at selecting suitable substituents for
decorating the aroyl moiety linked to the piperazine central core.
Then, we synthesized the designed compounds, which were
screened in biological assays. The most promising inhibitor was
crystallized in complex with TyBm.2. Results and discussion
2.1. Investigation into the fundamental interactions between
derivative 5b and TyM
Considering as a starting point the best docking pose of com-
pound 5b in the TyM active site, we calculated all plausible phar-
macophore interactions for TyM catalytic pocket by using the tool
“Apo Site Grid”, implemented in the LigandScout software vs 4.3
[14].
The obtained grid (Fig. 2)highlights areas of the binding pocket
in which the presence of particular features (i.e. H-bond donor, H-
bond acceptor, aromatic ring, hydrophobic groups, negative and
positive ionisable groups), would be favourable for the interaction
with the target protein. Our focus was especially placed on the aroyl
moiety of compound 5b with the purpose of exploring the wide
region in which it is positioned.
As expected, the inhibitor is surrounded by a hydrophobic grid
(yellow grid) in the middle and top areas of the cavity (Fig. 2A).
Instead, the presence of an aromatic ring (blue grid) seems to be
more favorable in the 4-ﬂuorobenzyl zone near the conserved
histidines. This evidence reinforces the observation that the
introduction of an aromatic moiety is relevant for the stabilization
of the inhibitors in the active site through the formation of p-
stacking interactions with the catalytic center. A small aromatic
zone also appears close to the o-tolyl group.
Finally, we have analyzed the grids related to H-bond donor
(green grid) or H-bond acceptor (red grid) features. As a result, we
found that the insertion of acceptor or donor groups might be
favorable on both the aromatic rings of compound 5b (Fig. 2 B).
Taking into account the obtained pharmacophore grids, we
planned the synthesis of a further series of compounds bearing
various substituents in ortho, para andmeta positions of the phenyl
ring. In particular, we selected chlorine and bromine atoms and
triﬂuoromethyl group considering both the hydrophobic
Fig. 1. Comparison of the binding pose of compound 5b in the catalytic cavities of TyM (A) and TyBm (B). Copper ions are presented as brown spheres, key residues of the pocket are
presented as grey sticks and hydrogen bond interactions by dotted lines. The picture was generated using PyMOL (https://pymol.org). (For interpretation of the references to color in
this ﬁgure legend, the reader is referred to the Web version of this article.)
Fig. 2. Apo Site Grid generated starting from the best docking pose of derivative 5b) in the catalytic site of TyM. A) Yellow grid highlights the favorable presence of hydrophobic
groups and speciﬁcally blue grid indicates aromatic rings. B) Green grid delineates H-bond donor and red grid H-bond acceptor. The picture was generated using Ligand Scout
software [14]. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the Web version of this article.)
Fig. 3. Plausible binding mode of compounds 13 (A) (orange stick) and 25 (B) (green stick) in the active site of TyM (PDB: 2Y9X). Copper ions are presented as brown spheres, key
residues of the pocket are presented as grey sticks and hydrogen bond interactions by dotted lines. The interactions between TyM and inhibitors 13 and 25 were examined using
PyMOL and LIGPLUS [16]. All structures presented were generated using PyMOL (https://pymol.org). (For interpretation of the references to color in this ﬁgure legend, the reader is
referred to the Web version of this article.)
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Fig. 4. LineweavereBurk plots for the inhibition of tyrosinase using to L-DOPA as the
substrate in the presence of compound 25.
Fig. 5. Structure of compound 25 bound in the active site of tyrosinase from TyBm
(PDB: 6QXD). Copper ions are presented as brown spheres and residues surrounding
the active site are shown as orange sticks. The structure presented was generated using
PyMOL (https://pymol.org). (For interpretation of the references to color in this ﬁgure
legend, the reader is referred to the Web version of this article.)
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Moreover, we chose to add nitro, amine and carboxyl groups as H-
bond acceptors/donors, as suggested by the red and green grids.
Based on previous structure-afﬁnity relationship information [13]
we also decided to synthesize several 2,4-disubstituted derivatives.
With the purpose to identify compounds with drug-like prop-
erties, we estimated physico-chemical parameters describing
pharmaco-kinetic behavior of drugs in the cell environment, i.e.
polar surface area, pKa, logP and logD at pH¼ 7 (https://
chemicalize.com/). These parameters were predicted for each
designed molecule and are reported in the Supporting Material
(Table S1). Furthermore, the presence of pan-assay interference
compounds (PAINS) and the conformity to Lipinski's rule were also
investigated by means of the free web tool Swiss ADME (http://
www.swissadme.ch/). According to the obtained results, all stud-
ied compounds displayed good permeability through the biological
membranes and no PAINS were detected.2.2. Chemical synthesis of inhibitors
As depicted in Scheme 1 the new designed 4-(4-ﬂuorobenzyl)piperazine-derivatives 7e25were synthesized by coupling benzoic
acids or benzoyl chlorides with 4-(4-ﬂuorobenzyl)piperazine 6 in
basic conditions. The 2,4-dihydroxy-derivative 26 was obtained by
treating the parent 2,4-dimethoxy analog (19) with boron tri-
bromide. Whereas, the amino-derivatives 27e30were prepared by
zinc-mediated nitroreduction of parent compounds (22e25). 1H
NMR spectra data of representative compounds are shown in
Supporting Material.
2.3. Inhibition of mushroom tyrosinase activity
Tyrosinase inhibitory activity was evaluated for all the synthe-
tized compounds using TyM and L-DOPA as a substrate. The ob-
tained results are summarized in Table 1. Overall, the synthesized
compounds showed a good inhibitory activity with IC50 values
lower or comparable to those of 5b 5a, and kojic acid (3) used as
reference compounds. Notably, the collected biological data was
coherent with in silico results suggested by pharmacophore grids.
It was interesting to note that the introduction of one substit-
uent such as nitro and triﬂuoromethyl group in ortho position of the
benzoyl ring allowed us to obtain more active compounds thus
reaching IC50 values at the nanomolar range for compounds 13
(0.48 mM) and 22 (0.87 mM). The meta amino derivative 28
demonstrated inhibitory effects with IC50 value of 3.81 mM,
whereas the ortho and meta analogs 27 and 29 possessed activity
comparable to those of unsubstituted inhibitor 5a (13.34 mM) and
kojic acid (3, 17.76 mM). Concerning the series of 2,4-disubstituted
derivatives, the most effective compounds were derivatives 17
(R¼ 2,4-Cl2) and 25 (R¼ 2,4-(NO2)2) having IC50 values of 0.79 and
0.96 mM, respectively.
2.4. Docking into TyM and kinetic studies
With the aim to investigate the binding mode of this series of
new designed derivatives we performed docking studies in the
active site of TyM from Agaricus bisporus retrieved from Protein
Data Bank (PDB: 2Y9X) by GOLD software [15]. Fig. 3 displays the
best poses found for the most interesting inhibitors 13
(IC50¼ 0.48 mM) and 25 (IC50¼ 0.96 mM).
As expected, the two inhibitors are positioned in the TyM active
site with the 4-ﬂuorobenzyl moiety placed towards the copper ions
and stabilized through p-p interaction with His263. Regarding
derivative 13 (Fig. 3A), we found an H-bond interaction between
the piperazine nitrogen atom and the carbonyl group of Asn260;
moreover, there is a bidentate H-bond interaction between the
carbonyl group of the benzamide moiety and the two residues
Ser282 and Val283. The triﬂuoromethyl substituent is oriented in
the hydrophobic area lined by residues Pro284 and Val283.
Concerning the docking pose of compound 25 (Fig. 3B), we
hypothesized that the nitro group at 20-position of the benzoyl
portion creates a polar contact with Arg268, while the nitro group
at 40-position forms an H-bonding interactionwith the side chain of
Thr261. Overall, the analysis of the interaction patterns found for
the best active inhibitors 13 and 25 conﬁrms that additional in-
teractions mediated by various substituents on the benzoyl portion
might justify an improvement of the afﬁnity toward the TyM active
site.
Kinetic studies on the diphenolase activity of TyM conﬁrmed the
hypothetical binding mode described for compound 25. Specif-
ically, the inhibitory mechanism was studied by using Lineweaver-
Burk double reciprocal plots and the results are displayed in Fig. 4.
The Lineweaver-Burk plot demonstrated that Vmax is the same
regardless of concentration of the inhibitor, and Km increases with
increasing concentrations of the inhibitor. This behavior indicates
that compound 25 acts as a competitive inhibitor and these
Scheme 1. Reagents and conditions: i) Suitable benzoyl chloride, DCM, EDIPA, MW: 10min, 50 C, 200W; ii) suitable benzoic acid, HBTU, TEA, DMF, rt, 24 h; iii) BBr3, DCM, 0 C, rt,
24 h; iv) HCl, Zn, EtOH, reﬂux, 2 h.
Table 1
Inhibitory activity of derivatives 7e30 compared to 5a, 5b and kojic acid (3) as
reference compounds.
cpd R Diphenolase activity IC50 (mM)a
7 2-Cl 3.12± 0.04
8 3-Cl 5.30± 0.40
9 4-Cl 3.51± 1.24
10 2-Br 2.03± 0.05
11 3-Br 2.40± 0.28
12 4-Br 4.61± 1.83
13 2-CF3 0.48± 0.05
14 3-CF3 8.43± 0.42
15 4-CF3 3.38± 0.07
16 2,4-F2 1.91± 0.13
17 2,4-Cl2 0.79± 0.11
18 2,4-(CF3)2 1.63± 0.11
19 2,4-(OCH3)2 1.40± 0.43
20 2,4-(CH3)2 3.43± 0.08
21 2,4-Br2 1.05± 0.09
22 2-NO2 0.87± 0.08
23 3-NO2 3.60± 0.07
24 4-NO2 2.05± 0.16
25 2,4-(NO2)2 0.96± 0.21
26 2,4-(OH)2 1.49± 0.32
27 2-NH2 10.94± 0.44
28 3-NH2 3.81± 0.56
29 4-NH2 14.66± 0.15
30 2,4-(NH2)2 3.67± 0.75
5a H 13.34± 0.73
5b 2-Me 5.25± 1.60
Kojic acid, 3 17.76± 0.18
a IC50 values represent the concentration that caused 50% enzyme activity loss. All
compounds were studied in a set of experiments performed in three replicates.
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To get more insight regarding the binding mode of the above
reported inhibitors within the active site of TYRs, crystallographicstudies were carried out using TyBm. We obtained a crystal struc-
ture of TyBm with bound compound 25 in the active site at a res-
olution of 2.3 Å (Fig. 5) (Table S2 and Fig. S1 as Supplementary
Material). The 4-ﬂuorobenzyl moiety of 25 is stabilized by p-p in-
teractions with His208 and is oriented toward CuA at a distance of
1.9 Å, similar to tyrosinase substrates [17] and to the TyM model
(Fig. 3B). Furthermore, a polar interaction is observed between
Arg209 and the oxygen atom of the carbonyl group in compound
25, similar to compound 5b as was previously reported (Fig. 1B)
[13].
The new synthesized derivatives and in particular compound 25
with positions 2,4-disubstituted with nitro groups, enabled the
formation of new interactions in the TyBm active site. These
possible intramolecular interactions were calculated using the Ar-
peggio server, based on geometrical and biochemical features [18].
Compound 25 is further stabilized in the active site by additional p-
p interactions observed between the aroyl ring and Phe197.
Furthermore, the aroyl ring also interacts with the amide group of
Asn205 (Fig. 6A).
Comparing the pose of compound 25 and the starting com-
pound 5b in the TyBm crystal structure reveals two main differ-
ences: (i) While the overall orientation of the 4-ﬂuorobenzyl
moiety is similar, this is the ﬁrst structure of TyBm with a ligand
positioned closer and in-between the two copper ions. This
outcome is derived from further interactions with surrounding key
amino acids in the active site shell, and supports the higher inhi-
bition rate by this compound. (ii) A major movement of Arg209 is
observed, which enabled the formation of a hydrogen bond with
the carbonyl group, thus stabilizing the bulky compound in the
active site (Fig. 6B). The ﬂexibility of Arg209 has been reported
beforehand, exhibiting alternative conformations that facilitate the
stabilization of ligands in the TyBm binding pocket [19]. It seems
that the combination of both the ﬂexibility of the diverse chemical
groups in derivatives 7e30 and the new interactions in the tyros-
inase active site results in a stronger inhibition effect. These data
appear coherent with docking results for TyM (see 2.4 section).2.6. Cell viability
After obtaining encouraging results from the assay experiments,
biosafety effectiveness of the promising compound 25 was further
Fig. 6. The 4-(4-ﬂuorobenzyl)piperazin-1-yl](2,4-dinitrophenyl)methanone (25) interactions in TyBm active site. A) Compound 25 (purple) is positioned in the active site of TyBm
with the oxygen atom of the carbonyl group forming a hydrogen bond with Arg209 (light blue dashed line). p-p interactions with His208 and Phe197 are presented in cyan dashed
lines, and amide-ring interaction with Asn205 is presented in a pink dashed line. B) Superposition with TyBm structure binding 4-(4-ﬂuorobenzyl)piperazin-1-yl](2-methylphenyl)
methanone (5b) (PDB: 6EI4). Compound 5b (yellow) and 25 (purple) are oriented through hydrophobic interactions with His208. Copper ions (brown) are identical whereas Arg209
is highly ﬂexible. All structures presented were generated using PyMOL (https://pymol.org). (For interpretation of the references to color in this ﬁgure legend, the reader is referred
to the Web version of this article.)
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ranging from 1 to 100 mM for 48 h at 37 C and their potential
cytotoxic effect on B16F10 cells was determined using the MTT test.
Compound 25 exhibited no cytotoxic effect until 10 mM (Fig. 7). As
previously reported in literature [20] the reference compound kojic
acid (3) is not cytotoxic at the same concentrations tested for the
compound 25.
Thus, further experiments using 10 mM of compound concen-
tration were performed.Fig. 8. Effect of compound 25 on B16F10 melanoma cells after incubation for 48 h.
Melanin production was expressed as percentage of the control and the effects of
extracts were compared with kojic acid as standard inhibitor, and DMSO. Data
represent mean± SD of triplicate experiments. Mean values in the column having
different letters are signiﬁcantly different (p< 0.05).2.6.1. Effect on cellular tyrosinase activity and melanin production
The inhibitory effect of compound 25 on the melanogenesis of
B16F10 cells treated with 100 nM a-MSH was examined. In the
experiments described here, a-MSH was used as a cAMP inducer to
stimulate melanin synthesis. Upon exposure to a-MSH alone, the
tyrosinase activity was signiﬁcantly increased, compared to un-
treated cells (Fig. 8). After 48 h of incubation with compound 25,
the melanin content of a -MSH-stimulated B16F10 cells was also
evaluated.
Fig. 8 shows that compound 25 resulted to be more effective as
an anti-melanogenic agent than kojic acid which did not show any
inhibition at the same concentration as compared with the control.
The results showed that compound 25 inhibited by 22.75± 0.48%Fig. 7. Effect of compound 25 on B16F10 cell viability. Cells were treated with different
concentrations of compound (1e100 mM) and their viability was evaluated by MTT
assay. Data represent mean ± SD of triplicate experiments.cellular melanogenesis induced by a-MSH-mediated intracellular
cAMP up-regulation.
3. Conclusions
In summary, we have investigated the TyM inhibitory effects of
twenty-four (4-(4-ﬂuorobenzyl)piperazine derivatives (7e30)
designed on the basis of in silico analysis. As result we have found
four superior active compounds 13, 17, 22 and 25 displaying IC50
values at nanomolar concentration as inhibitors using L-DOPA as a
substrate. Among these promising molecules, compound 25 (IC50
value of 0.96 mM) was nearly 20-fold more active than the positive
control kojic acid 3 (IC50 17.76 mM) and revealed to be a competitive
inhibitor. Compound 25 also proved to exhibit no considerable
cytotoxic effect in B16F10melanoma cells at the concentration used
to determinate the cell melanin production.
Moreover, this compound resulted to be more effective as anti-
melanogenic agent when compared with reference compound 3
suggesting a good correlation between mushroom tyrosinase
inhibitory properties andmelanoma cellular effects. By means of X-
L. Ielo et al. / European Journal of Medicinal Chemistry 178 (2019) 380e389386ray and docking studies we demonstrated that compound 25 is able
to bind at the catalytic site of tyrosinase for which the 4-
ﬂuorobenzyl moiety represents the driving force for the best
interaction in the deep region near to copper ions. Moreover, the
presence of suitable moieties such as a 2,4-dinitrophenyl group
created additional contacts in the top area of the catalytic site thus
improving the binding afﬁnity. Overall, these data might be useful
to further investigate anti-melanogenic agents from synthetic
source structurally related to the best active prototype 25.
4. Experimental
4.1. Chemistry
All reagents were used without further puriﬁcation and bought
from common commercial suppliers. Microwave-assisted reactions
were carried out in a Focused Microwawe TM Synthesis System,
Model Discover (CEM Technology Ltd Buckingham, UK). Melting
points were determined on a Buchi B-545 apparatus (BUCHI
Labortechnik AG Flawil, Switzerland) and are uncorrected. By
combustion analysis (C, H, N) carried out on a Carlo Erba Model
1106-Elemental Analyzer we determined the purity of synthesized
compounds; the results conﬁrmed a 95% purity. Merck Silica Gel
60 F254 plates were used for analytical TLC (Merck KGaA, Darm-
stadt, Germany). For detection, iodine vapor and UV light (254 nm)
were used. Flash Chromatography (FC) was carried out on a Biotage
SP1 EXP (Biotage AB Uppsala, Sweden). 1H NMR spectra were
measured in dimethylsulfoxide-d6 (DMSO‑d6) or CDCl3 with a
Varian Gemini 300 spectrometer (Varian Inc. Palo Alto, California
USA); chemical shifts are expressed in d (ppm) and coupling con-
stants (J) in hertz. All exchangeable protons were conﬁrmed by
addition of D2O. 13C NMR spectra and mass spectra of selected
compounds were measured in chloroform (CDCl3) with a Varian
and Mass Spectrometer API 2000 respectively.
4.1.1. General procedure for the synthesis of [4-(4-Fluorobenzyl)
piperazin-1-yl]methanone derivatives (7e19)
To a solution of 1-(4-ﬂuorobenzyl)piperazine (6) (0.5mmol) in
DCM (2mL) the N,N-diisopropylethylamine (0.75mmol) and the
suitable benzoyl chloride (0.5mmol) were added. The reaction was
carried as previously reported. The ﬁnal products 7e19 were pu-
riﬁed by crystallization with Et2O or by ﬂash chromatography. For
compounds 7e12, 15,16 registered CAS numbers have been already
assigned. However, their synthetic procedures, chemical properties
and structural characterization are not available in literature.
4.1.2. [4-(4-Fluorobenzyl)piperazin-1-yl](2-chlorophenyl)
methanone (7)
CAS number: 439847-31-1. Yield 60%. White solid. M.p.
94e95 C. 1H NMR (CDCl3) (d): 7.32 (mc, 6H, ArH), 7.00 (mc, 2H,
ArH), 3.81 (mc, 2H, CH2), 3.49 (s, 2H, CH2), 3.22 (mc, 2H, CH2), 2.41
(mc, 4H, CH2). Anal. Calcd for (C18H18ClFN2O): C 65.00, H 5.50, N
8.40. Found: C 65.20, H 5.48, N 8.09.
4.1.3. [4-(4-Fluorobenzyl)piperazin-1-yl](3-chlorophenyl)
methanone (8)
CAS number: 423748-71-4. Yield 70%. Oily residue. 1H NMR
(CDCl3) (d): 7.33 (mc, 6H, ArH), 7.01 (mc, 2H, ArH), 3.78 (mc, 2H,
CH2), 3.50 (s, 2H, CH2), 3.41 (mc, 2H, CH2), 2.51 (mc, 2H, CH2), 2.37
(mc, 2H, CH2). Anal. Calcd for (C18H18ClFN2O): C 65.00, H 5.50, N
8.40. Found: C 65.18, H 5.44, N 8.60.
4.1.4. [4-(4-Fluorobenzyl)piperazin-1-yl](4-chlorophenyl)
methanone (9)
CAS number: 945173-43-3. Yield 50%. White solid. M.p.81e82 C. 1H NMR (CDCl3) (d): 7.32 (mc, 6H, ArH), 7.00 (mc, 2H,
ArH), 3.82 (mc, 2H, CH2), 3.49 (s, 2H, CH2), 3.22 (mc, 2H, CH2), 2.47
(mc, 4H, CH2). Anal. Calcd for (C18H18ClFN2O): C 65.00, H 5.50, N
8.40. Found: C 65.15, H 5.59, N 8.44.4.1.5. [4-(4-Fluorobenzyl)piperazin-1-yl](2-bromophenyl)
methanone (10)
CAS number: 1326972-94-4. Yield 50%. White solid. M.p.
86e87 C. 1H NMR (CDCl3) (d): 7.56 (mc, 1H, ArH), 7.30 (mc, 5H,
ArH), 6.99 (mc, 2H, ArH), 3.82 (mc, 2H, CH2), 3.49 (s, 2H, CH2), 3.23
(mc, 2H, CH2), 2.44 (mc, 4H, CH2). Anal. Calcd for (C18H18BrFN2O): C
57.30, H 4.80, N 7.40. Found: C 57.21, H 4.75, N 7.44.4.1.6. [4-(4-Fluorobenzyl)piperazin-1-yl](3-bromophenyl)
methanone (11)
CAS number: 439844-72-1. Yield 60%. Oily residue. 1H NMR
(CDCl3) (d): 7.54 (mc, 1H, ArH), 7.28 (mc, 5H, ArH), 7.01 (mc, 2H,
ArH), 3.77 (mc, 2H, CH2), 3.49 (s, 2H, CH2), 3.40 (mc, 2H, CH2), 2.51
(mc, 2H, CH2), 2.37 (mc, 2H, CH2). Anal. Calcd for (C18H18BrFN2O): C
57.30, H 4.80, N 7.40. Found: C 57.48, H 4.29, N 7.60.4.1.7. [4-(4-Fluorobenzyl)piperazin-1-yl](4-bromophenyl)
methanone (12)
CAS number: 439844-65-2. Yield 55%. White solid. M.p.
87e88 C. 1H NMR (CDCl3) (d): 7.53 (mc, 1H, ArH), 7.30 (mc, 5H,
ArH), 7.00 (mc, 2H, ArH), 3.76 (mc, 2H, CH2), 3.49 (s, 2H, CH2), 3.40
(mc, 2H, CH2), 2.40 (mc, 4H, CH2). Anal. Calcd for (C18H18BrFN2O): C
57.30, H 4.80, N 7.40. Found: C 57.25, H 4.88, N 7.30.4.1.8. [4-(4-Fluorobenzyl)piperazin-1-yl](2-triﬂuoromethyl)
methanone (13)
Yield 90%. Oily residue. 1H NMR (CDCl3) (d): 7.69 (d, J¼ 7.3 Hz,
1H, ArH), 7.53 (mc, 2H, ArH), 7.28 (mc, 3H, ArH), 6.99 (mc, 2H, ArH),
3.81 (t, J¼ 5.0 Hz, 2H, CH2), 3.48 (s, 2H, CH2), 3.16 (t, J¼ 5.0 Hz, 2H,
CH2), 2.50 (mc, 2H, CH2), 2.29 (mc, 2H, CH2). Anal. Calcd for
(C19H18F4N2O): C 62.29, H 4.95, N 7.65. Found: C 62.39, H 4.61, N
7.48.4.1.9. [4-(4-Fluorobenzyl)piperazin-1-yl](3-triﬂuoromethyl)
methanone (14)
Yield 92%. Oily residue. 1H NMR (CDCl3) (d): 7.67 (mc, 2H, ArH),
7.56 (mc, 2H, ArH), 7.27 (mc, 2H, ArH), 7,00 (mc, 2H, ArH), 3.79 (mc,
2H, CH2), 3.50 (s, 2H, CH2), 3.39 (mc, 2H, CH2), 2.45 (mc, 4H, CH2).
Anal. Calcd for (C19H18F4N2O): C 62.29, H 4.95, N 7.65. Found: C
62.19, H 4.85, N 7.36.4.1.10. [4-(4-Fluorobenzyl)piperazin-1-yl](4-triﬂuoromethyl)
methanone (15)
CAS number: 1329056-52-1. Yield 87%. White solid. M.p.
82.8e84.5 C. 1H NMR (CDCl3) (d): 7.66 (d, J¼ 8.2 Hz, 2H, ArH), 7.50
(d, J¼ 8.2 Hz, 2H, ArH), 7.27 (mc, 2H, ArH), 7.00 (mc, 2H, ArH), 3.80
(mc, 2H, CH2), 3.50 (s, 2H, CH2), 3.37 (mc, 2H, CH2), 2.44 (mc, 4H,
CH2). Anal. Calcd for (C19H18F4N2O): C 62.29, H 4.95, N 7.65. Found:
C 62.50, H 4.77, N 7.45.4.1.11. [4-(4-Fluorobenzyl)piperazin-1-yl](2,4-diﬂuorophenyl)
methanone (16)
CAS number: 1388318-37-3. Yield 50%. White solid. M.p.
88e90 C. 1H NMR (CDCl3) (d): 7.34 (mc, 3H, ArH), 6.91 (mc, 4H,
ArH), 3.79 (mc, 2H, CH2), 3.49 (s, 2H, CH2), 3.32 (mc, 2H, CH2), 2.44
(mc, 4H, CH2). Anal. Calcd for (C18H17F3N2O): C 64.66, H 5.13, N 8.38.
Found: C 64.78, H 5.08, N 8.50.
L. Ielo et al. / European Journal of Medicinal Chemistry 178 (2019) 380e389 3874.1.12. [4-(4-Fluorobenzyl)piperazin-1-yl](2,4-dichlorophenyl)
methanone (17)
Yield 65%. Oily residue. 1H NMR (CDCl3) (d): 7.41 (mc, 1H, ArH),
7.24 (mc, 4H, ArH), 7.00 (mc, 2H, ArH), 3.80 (mc, 2H, CH2), 3.49 (s,
2H, CH2), 3.24 (mc, 2H, CH2), 2.47 (mc, 3H, CH2), 2.32 (mc, 1H, CH2).
Anal. Calcd for (C18H17Cl2FN2O): C 58.87, H 4.67, N 7.63. Found: C
58.90, H 4.44, N 7.78.
4.1.13. [2,4-Bis(triﬂuoromethyl)phenyl][4-(4-ﬂuorobenzyl)
piperazin-1-yl]methanone (18)
Yield 80%. White solid. m.p. 75e77 C. 1H NMR (DMSO) (d): 8.13
(mc, 2H, ArH), 7.73 (mc, 1H, ArH), 7.21 (mc, 2H, ArH), 7.12 (m, 2H,
ArH), 3.50 (s, 2H, CH2), 3.69e2.07 (m, 8H, CH2). 13C NMR (DMSO‑d6)
(d): 164.65 (CO), 162.24 (CF), 160.30 (CF), 138.75, 133.86, 130.70,
128.97, 129.98, 129.74, 126.48, 123.77, 114.80, 60.71, 51.98, 51.65,
46.57, 41.18 Anal. Calcd for (C20H17F7N2O) C 55.31, H 3.94, N 6.45.
Found: C 55.21, H 3.84, N 6.35.
4.1.14. [4-(4-Fluorobenzyl)piperazin-1-yl](2,4-dimethoxyphenyl)
methanone (19)
Yield 50%. White solid. M.p. 97e98 C. 1H NMR (CDCl3) (d): 7.22
(mc, 3H, ArH), 6.99 (mc, 2H, ArH), 6.46 (mc, 2H, ArH), 3.80 (s, 3H,
CH3), 3.79 (mc, 2H, CH2), 3.78 (s, 3H, CH3), 3.47 (s, 2H, CH2), 3.25
(mc, 2H, CH2), 2.39 (mc, 4H, CH2). Anal. Calcd for (C20H23FN2O3): C
67.00, H 6.50, N 7.80. Found: C 67.15, H 6.42, N 7.73.
4.1.15. General procedure to synthesize [4-(4-Fluorobenzyl)
piperazin-1-yl]methanone derivatives (20e25)
A mixture of the suitable carboxylic acid derivative (1mmol),
N,N,N0,N0-tetramethyl-O-(1H-benzotriazol-1-yl)uranium hexa-
ﬂuorophosphate (HBTU) (1mmol, 380mg) in DMF (4mL) was
stirred at room temperature for 1 h. Then, a solution of the 1-(4-
ﬂuorobenzyl)pyperazine (6) (1mmol) in TEA (1mmol, 140 mL)
was added dropwise. The reaction has been accomplished as pre-
viously reported [21]. The ﬁnal compounds 20e25were puriﬁed by
crystallization with Et2O or by ﬂash chromatography. For com-
pounds 23, 24 registered CAS numbers have been already assigned.
However, their synthetic procedures, chemical properties and
structural characterization are not available in literature.
4.1.16. [4-(4-Fluorobenzyl)piperazin-1-yl](2,4-dimethylphenyl)
methanone (20)
Yield 56%. White solid. M.p. 247e249 C. 1H NMR (CDCl3) (d):
7.66 (mc, 2H, ArH), 7.13 (t, J¼ 8.6 Hz, 2H, ArH), 7.02 (mc, 3H, ArH),
4.15 (mc, 2H, CH2), 4.00 (mc, 1H, CH2), 3.73 (mc, 1H, CH2), 3.56 (mc,
2H, CH2), 3.30 (mc, 1H, CH2), 2.71 (mc, 3H, CH2), 2.31 (s, 3H, CH3),
2.23 (s, 3H, CH3). 13C NMR (CDCl3) (d): 170.24 (CO), 162.81 (CF),
139.86, 134.45, 133.46, 131.55, 126.80, 116.65, 60.36, 51.31, 21.20,
19.00. MS (ESI):m/z: 327.0 [MþHþ]. Anal. Calcd for (C20H23FN2O): C
73.59, H 7.10, N 8.58. Found: C 73.40, H 7.28, N 8.40.
4.1.17. [4-(4-Fluorobenzyl)piperazin-1-yl](2,4-dibromophenyl)
methanone (21)
Yield 80%. Oily residue. 1H NMR (CDCl3) (d): 7.73 (mc, 1H, ArH),
7.49 (d, J¼ 8.2 Hz,1H, ArH), 7.27 (mc, 2H, ArH), 7.12 (d, J¼ 8.2 Hz 1H,
ArH), 7.00 (mc, 2H, ArH), 3.80 (t, J¼ 5.2 Hz, 2H, CH2), 3.50 (s, 2H,
CH2), 3.23 (mc, 2H, CH2), 2.45 (mc, 3H, CH2), 2.33 (mc, 1H, CH2).
Anal. Calcd for (C18H17Br2FN2O): C 47.40, H 3.76, N 6.14. Found: C
47.55, H 3.52, N 6.20.
4.1.18. [4-(4-Fluorobenzyl)piperazin-1-yl](2-nitrophenyl)
methanone (22)
Yield 70%. Bright yellow solid. M.p. 101e102 C. 1H NMR (CDCl3)
(d): 8.18 (d, J¼ 7.7 Hz, 1H, ArH), 7.69 (t, J¼ 7.7 Hz, 1H, ArH), 7.55 (t,
J¼ 7.7 Hz, 1H, ArH), 7.38 (d, J¼ 7.7 Hz, 1H, ArH), 7.27 (t, J¼ 8.5 Hz,2H, ArH), 6.99 (t, J¼ 8.5 Hz, 2H, ArH), 3.83 (mc, 2H, CH2), 3.49 (s, 2H,
CH2), 3.21 (t, J¼ 5.1 Hz, 2H, CH2), 2.57 (mc, 2H, CH2), 2.35 (mc, 2H,
CH2). Anal. Calcd for (C18H18FN3O3): C 63.00, H 5.30, N 12.20.
Found: C 63.33, H 5.28, N 12.31.
4.1.19. [4-(4-Fluorobenzyl)piperazin-1-yl](3-nitrophenyl)
methanone (23)
CAS number: 439847-09-3. Yield 76%. Bright yellow solid. M.p.
110e112 C. 1H NMR (CDCl3) (d): 8.28 (mc, 1H, ArH), 7.74 (d,
J¼ 7.4 Hz, 1H, ArH), 7.62 (mc, 1H, ArH), 7,28 (mc, 3H, ArH), 7.00 (mc,
2H, ArH), 3.80 (mc, 2H, CH2), 3.51 (s, 2H, CH2), 3.39 (mc, 2H, CH2),
2.55 (mc, 2H, CH2), 2.26 (mc, 2H, CH2). Anal. Calcd for
(C18H18FN3O3): C 63.00, H 5.30, N 12.20. Found: C 63.10, H 5.24, N
12.01.
4.1.20. [4-(4-Fluorobenzyl)piperazin-1-yl](4-nitrophenyl)
methanone (24)
CAS number: 356090-43-2. Yield 80%. Bright yellow solid. M.p.
123e124 C. 1H NMR (CDCl3) (d): 8.27 (d, J¼ 8.6 Hz, 2H, ArH), 7.56
(d, J¼ 8.6 Hz, 2H, ArH), 7.27 (t, J¼ 8.7 Hz, 2H, ArH), 7.00 (t,
J¼ 8.7 Hz, 2H, ArH), 3.80 (mc, 2H, CH2), 3.51 (s, 2H, CH2), 3.36 (mc,
2H, CH2), 2.53 (mc, 2H, CH2), 2.37 (mc, 2H, CH2). Anal. Calcd for
(C18H18FN3O3): C 63.00, H 5.30, N 12.20. Found: C 63.29, H 5.04, N
12.44.
4.1.21. [4-(4-Fluorobenzyl)piperazin-1-yl](2,4-dinitrophenyl)
methanone (25)
Yield 62%. Yellow solid. M.p. 169e171 C. 1H NMR (CDCl3) (d):
9.01 (s, 1H, ArH), 8.54 (d, J¼ 8.3 Hz, 1H, ArH), 7.61 (d, J¼ 8.3 Hz, 1H,
ArH), 7.28 (mc, 2H, ArH), 7.00 (t, J¼ 8.7 Hz, 2H, ArH), 3.84 (mc, 2H,
CH2), 3.52 (s, 2H, CH2), 3.21 (t, J¼ 5.0 Hz, 2H, CH2), 2.58 (mc, 2H,
CH2), 2.38 (mc, 2H, CH2). 13C NMR (CDCl3) (d): 164.14 (CO), 163.12
(CF), 147.95, 145.74, 138.22, 133.10, 130.50, 129.59, 128.65, 120.44,
115.21, 61.91, 52.11, 46.91. MS (ESI):m/z: 388.8 [MþHþ]. Anal. Calcd
for (C18H17FN4O5): C 55.67, H 4.41, N 14.43. Found: C 55.59, H 4.30, N
14.15.
4.1.22. Synthetic procedure for [4-(4-ﬂuorobenzyl)piperazin-1-
yl](2,4-dihydroxyphenyl)methanone (26)
Compound 26 was synthesized following a previously reported
procedure [20]. The ﬁnal product 26was puriﬁed by treatmentwith
MeOH. Yield 60%. Oily residue. 1H NMR (CDCl3) (d): 7.27 (t,
J¼ 8.5 Hz, 2H, ArH), 7.07 (d, J¼ 8.5 Hz, 1H, ArH), 6.99 (t, J¼ 8.5 Hz,
2H, ArH), 6.37 (mc, 1H, ArH), 6.27 (d, J¼ 8.5 Hz, 1H, ArH), 3.69 (mc,
4H, CH2), 3.50 (s, 2H, CH2), 2.48 (mc, 4H, 2 CH2). Anal. Calcd for
(C18H19FN2O3): C 65.44, H 5.80, N 8.48; Found: C 65.55, H 5.74, N
8.59.
4.1.23. General procedure to synthesize aminophenyl derivatives
27-30
Compounds 22e25 were synthesized following a previously
reported procedure [22] giving the desired amino-analogues
27e30 through puriﬁcation with EtOH.
4.1.24. [4-(4-Fluorobenzyl)piperazin-1-yl](2-aminophenyl)
methanone (27)
Yield 80%. Oily residue. 1H NMR (CDCl3) (d): 7.27 (mc, 2H, ArH),
7.14 (mc, 1H, ArH), 7.04 (mc, 3H, ArH), 6.68 (mc, 2H, ArH), 4.31 (bs,
2H, NH2), 3.62 (mc, 4H, CH2), 3.48 (s, 2H, CH2), 2.43 (mc, 4H, CH2).
Anal. Calcd for (C18H20FN3O): C 68.99, H 6.43, N 13.41. Found: C
69.05, H 6.43, N 13.66.
4.1.25. [4-(4-Fluorobenzyl)piperazin-1-yl](3-aminophenyl)
methanone (28)
Yield 85%. Oily residue. 1H NMR (CDCl3) (d): 7.26 (mc, 3H, ArH),
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2H, CH2), 3.43 (mc, 2H, CH2), 2.45 (mc, 4H, CH2). Anal. Calcd for
(C18H20FN3O): C 68.99, H 6.43, N 13.41. Found: C 69.28, H 6.66, N
13.25.
4.1.26. [4-(4-Fluorobenzyl)piperazin-1-yl](4-aminophenyl)
methanone (29)
Yield 80%. White solid. M.p. 146e148 C. 1H NMR (CDCl3) (d):
7.27 (mc, 4H, ArH), 7.00 (t, J¼ 8.8 Hz, 2H, ArH), 6.63 (d, J¼ 8.8 Hz,
2H, ArH), 3.85 (mc, 2H, CH2), 3.62 (mc, 2H, CH2), 3.48 (s, 2H, CH2),
2.43 (mc, 4H, CH2). 13C NMR (CDCl3) (d): 170.85 (CO), 163.20 (CF),
148.21, 133.57, 130.72, 129.46, 125.36, 115.22, 114.30, 62.27, 53.21.
MS (ESI):m/z: 314.0 [MþHþ]. Anal. Calcd for (C18H20FN3O): C 68.99,
H 6.43, N 13.41. Found: C 69.78, H 6.77, N 13.50.
4.1.27. [4-(4-ﬂuorobenzyl)piperazin-1-yl](2,4-diaminophenyl)
methanone (30)
Yield 74%. Oily residue. 1H NMR (CDCl3) (d): 7.25 (mc, 2H, ArH),
7.01 (mc, 2H, ArH), 6.88 (mc, 1H, ArH), 6.00 (mc, 2H, ArH), 3.61 (t,
J¼ 5.0 Hz, 4H, CH2), 3.47 (s, 2H, CH2), 2.42 (t, J¼ 5.0 Hz, 4H, CH2).
Anal. Calcd for (C18H21FN4O): C 65.84, H 6.45, N 17.06. Found: C
65.44, H 6.30, N 16.88.
4.2. Mushroom tyrosinase inhibition assay
The assay was performed according to the method previously
reported [13]. A pre-incubation mixture consisted of samples
(0.2e20 mM), L-DOPA (1.25mM), sodium acetate buffer (0.05M, pH
6.8) at 25 C for 10min. After incubation, mushroom tyrosinase
(TyM, 333 U/mL) (EC 1.14.18.1 from Sigma Chemical Company) was
added to the mixture. The amount of dopachrome in the reaction
mixture was immediately measured as absorbance at 475 nm up to
5min.
The extent of inhibition, expressed as inhibition percentage, was
calculated as follows:
Inhibition % ¼

A B
A

x 100
where A and B represent the absorbance at 475 nm for the blank
and sample, respectively. The concentrations leading to 50% activity
lost (IC50) were also calculated. Kojic acid was used as a reference
standard.
4.3. Kinetic analysis of the tyrosinase inhibition
The reaction mixture consisted of four different concentrations
of L-DOPA (0.6e5mM), the substrate, and TyM in acetate buffer
(0.05M, pH 6.8). Three different concentrations of compound 25
(0.48, 0.96, and 1.92 mM) were added to the reaction mixture. The
MichaelisMenten constant (Km) and maximal velocity (Vmax) of
tyrosinase were determined by LineweaverBurk plots.
4.4. Computational studies
4.4.1. Generation of pharmacophore-grid
The Apo-Site grids were created by using LigandScout Suite vs
4.3. The docking pose of inhibitor 5b into TyM active site was
employed as starting point for the pharmacophore-grids genera-
tion considering the residues within 5Å from the ligand.
4.4.2. Docking analysis
The crystal structure of Agaricus Bisporus TyM in complex with
inhibitor tropolone was retrieved from the RCSB Protein Data Bank
(PDB code 2Y9X). The protein and ligands 7e30 were prepared byDiscovery Studio 2.5.5 [23] and we used all structures to setup
docking simulation by Gold 5.0.1 [15]. The above-mentioned pro-
cedures are described in detail in previous papers [12,13], the
procedures were carried out through slight modiﬁcations. Specif-
ically, the side chains of residues His244, Val248, His251, Met257,
Asn260, Thr261, Phe264, Arg268 and Leu275 were allowed to
rotate according to the internal rotamer libraries in GOLD Suite
5.0.1. The molecular models of the docked compounds were dis-
played using Pymol software.
4.5. Crystallization and data collection
TyBm crystals were prepared as described previously [17].
Mature crystals were soaked overnight with 1 mL of 10mM inhib-
itor 25 dissolved in 100% DMSO and 1 mL of 5mM CuSO4 in 25% PEG
8K. Data from X-ray diffraction was obtained at the European
Synchrotron Radiation Facility (Grenoble, France), at beamline ID
23-1. X-ray diffraction data was indexed, integrated, scaled, and
merged using Mosﬂm and Scala programs [24]. The structure of
TyBm in complex with compound 25 was solved using the co-
ordinates of the already determined TyBm structure (PDB 4P6R),
and molecular replacement using Phaser [25]. Cycles of reﬁnement
were performed using Phenix [26] and Refmac [27,28] along with
real-space reﬁnement, manual model building and structure vali-
dation using COOT [29]. Information about the collected data,
phasing process, and reﬁnement statistics are presented in Table S2
in Supplementary Material.
4.6. Cell line and culture conditions
B16F10mousemelanoma cells (CRL-6475) were purchased from
the American Type Culture Collection (ATCC, Manassas, VA, USA).
The cells were cultured in Dulbecco's Modiﬁed Eagle Medium
(DMEM) supplemented with 10% fetal bovine serum (FBS, Gibco,
NY, USA), and 1% penicillin/streptomycin at 37 C in a humidiﬁed
atmosphere with 5% CO2.
4.7. MTT assay for cell viability
The cytotoxic effect of compound 25 was evaluated in
B16F10 cells using 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay [30]. Brieﬂy, cells were
seeded in a 96-well plate (5x103 cells/well) and incubated at 37 C
with samples at concentration ranging from 1 to 100 mM for 48 h.
DMSO was used as solvent for compounds, all activities were per-
formed also in the presence of DMSO alone, as solvent control. After
incubation time, cells were labelled with MTT solution for 3 h at
37 C. The resulting violet formazan precipitates were dissolved in
DMSO and color development was measured at 570 nm using a
microplate reader (Inﬁnite 200, Tecan, Austria). The absorbance
was proportional to the number of viable cells.
4.8. Intracellular melanin content assay
B16F10 cells were grown in 75-cm2 culture ﬂask at a density
105 cells/mL. After 24 h, the medium was substituted by fresh one
supplemented with 100 nM a-MSH with 10 mM of compound 25
and incubated for 48 h. Cells treated with 100 nM a-MSH and kojic
acid were used as positive control and for comparing the inhibitory
strength of the compound. After incubation for 48 h cells were
harvested and melanin content in B16F10 cells were measured
following a previously describedmethod [31]. Standard curve using
synthetic melanin was prepared for each experiment. Intracellular
melanin content was calculated by normalizing the melanin value
with protein content (mg of melanin/mg of cellular protein) and
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4.9. Statistical analyses
Statistical differences were evaluated using GraphPad Prism
software (San Diego, CA, USA). Comparison between groups was
assessed by oneeway analysis of variance (Oneeway ANOVA) fol-
lowed by the Bonferroni Multiple Comparisons Test. The values
with p< 0.05 were considered signiﬁcant.
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